Manufacturing Compliance Updates In Brief From US FDA And EU
Executive Summary
Data integrity problems reemerged as a theme in seven recent drug GMP warning letters the US FDA sent to drug and active ingredient manufacturers at sites in South Korea, Australia, Taiwan, China, Ireland and France. Investigators also are seeing problems with inadequate testing of components and inattention to investigating batch failure. FDA issued a Form 483 report to Glenmark in India for inadequate cross-contamination controls, in the EU, the Spanish Agency of Medicines and Medical Devices withdrew one Spanish drug maker’s GMP certificate for multiple GMP violations.
You may also be interested in...
FDA Warns Glenmark Over Temperature Excursions, Gritty Topicals
Firm should have addressed complaints of gritty topicals and compromised container/closures, and its own findings about overheated creams, the US FDA says.
The Next New Thing In FDA Inspections: Poor Root Cause Investigations
Data integrity failures are so yesterday. Now it’s all about poor investigations into out-of-specification results.
FDA Expects Drug GMP Warning Letter Tally To Reach 90 This Year
FDA official says OTC firms that have not been inspected before and have limited to no knowledge of US GMP requirements appear to be driving the upward surge in drug GMP warning letters issued by the agency since January. One especially “scary” warning letter trend is manufacturers not testing incoming ingredient for diethylene glycol (DEG) or ethylene glycol (EG). Over the years, DEG contamination in pharmaceuticals has resulted in lethal poisoning incidents around the world.